. From, S. Locarnini, and F. Zoulim, Molecular genetics of HBV infection, Antivir Ther, vol.15, p.324, 2010.

S. Schadler,

E. Hildt, HBV life cycle: entry and morphogenesis, Viruses, vol.1, pp.185-209, 2009.

T. M. Block, H. Guo, and J. T. Guo, Molecular virology of hepatitis B virus for clinicians, Clin Liver Dis, vol.326, pp.685-706, 2007.

D. Cai, C. Mills, W. Yu, R. Yan, C. E. Aldrich et al., , p.328

A. and G. H. , Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B 329 virus covalently closed circular DNA formation, Antimicrob Agents Chemother, vol.56, pp.4277-4288, 2012.

W. R. Kim, Emerging therapies toward a functional cure for hepatitis B virus infection, Gastroenterol, vol.331, 2018.

, Hepatol (N Y), vol.14, pp.439-442

A. G. Cole, Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection, 2016.

, Curr Opin Pharmacol, pp.131-137

A. Diab, A. Foca, F. Zoulim, D. Durantel, and O. Andrisani, The diverse functions of the hepatitis B 335 core/capsid protein (HBc) in the viral life cycle: implications for the development of HBc-targeting antivirals, 2018.

, Antiviral Res, vol.149, pp.211-220

S. Boucle, L. Bassit, M. Ehteshami, and R. F. Schinazi, Toward elimination of hepatitis B virus using novel 338 drugs, approaches, and combined modalities, Clin Liver Dis, vol.20, pp.737-749, 2016.

G. Wu, B. Liu, Y. Zhang, J. Li, A. Arzumanyan et al., , p.340

F. Zhang and M. A. Feitelson, Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core 341 particle assembly, Antimicrob Agents Chemother, vol.57, pp.5344-54, 2013.

S. P. Katen, S. R. Chirapu, M. G. Finn, and A. Zlotnick, Trapping of hepatitis B virus capsid assembly 343 intermediates by phenylpropenamide assembly accelerators, ACS Chem Biol, vol.5, pp.1125-1136, 2010.

M. R. Campagna, F. Liu, R. Mao, C. Mills, D. Cai et al., , p.345

T. M. Block and J. T. Guo, Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus 346 nucleocapsids, J Virol, vol.87, pp.6931-6942, 2013.

E. J. Gane, C. Schwabe, K. Walker, L. Flores, G. D. Hartman et al., Phase 348 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor, LB19. b), vol.349, p.350, 2014.

K. Klumpp, Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator 351 against hepatitis B virus, Antimicrob Agents Chemother, vol.63, pp.1734-1752, 2018.

N. Mani, A. G. Cole, J. R. Phelps, A. Ardzinski, K. D. Cobarrubias et al., Fan, vol.353

K. , G. F. Guo, H. Guo, J. T. Harasym, T. O. Kadhim et al., , p.354

R. Mao, K. D. Mcclintock, S. P. Reid, R. Rijnbrand, N. M. Snead et al., , vol.355

X. Zhao, Q. Sofia, and M. J. , Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA 356 encapsidation, Antimicrob Agents Chemother, vol.62, pp.82-100, 2018.

N. Mani, A. Li, A. Ardzinski, L. Bailey, J. R. Phelps et al., , p.358

E. Evangelista, D. Gotchev, T. O. Harasym, A. Jarosz, S. Kadhim et al., , vol.360, p.17

X. Teng, M. Wong, and M. J. Sofia, Preclinical antiviral drug combination studies utilizing novel orally 361 bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid 362 inhibitor, and AB-452, an HBV RNA destabilizer, J Hepatol, vol.68, p.17, 2018.

M. F. Yuen, K. Agarwal, G. Gane, C. Schwabe, W. Cheng et al., , p.365

K. Visvanathan, E. Ruby, S. Liaw, R. Colonno, and U. Lopatin, Interim safety, tolerability pharmacokinetics, 366 and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers, and non-367 cirrhotic viremic subjects with chronic hepatitis B, J Hepatol, vol.68, p.111, 2018.

O. Sari, S. Boucle, B. D. Cox, T. Ozturk, O. Russell et al., Synthesis of 369 sulfamoylbenzamide derivatives as HBV capsid assembly effector, Eur J Med Chem, vol.138, pp.407-421, 2017.

S. D. Pas, E. Fries, R. A. De-man, A. D. Osterhaus, and H. G. Niesters, Development of a quantitative real-time 371 detection assay for hepatitis B virus DNA and comparison with two commercial assays, J Clin Microbiol, vol.372, pp.2897-2901, 2000.

M. C. Lo, A. Aulabaugh, G. Jin, R. Cowling, J. Bard et al., Evaluation of 374 fluorescence-based thermal shift assays for hit identification in drug discovery, Anal Biochem, vol.332, pp.153-159, 2004.

J. Tang, A. D. Huber, D. L. Pineda, K. N. Boschert, J. J. Wolf et al., -Aminothiophene-2, 4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors, Eur. J. Med, vol.376, issue.5, 2019.

, Chem, vol.164, pp.179-192

T. Lahlali, J. M. Berke, K. Vergauwen, A. Foca, K. Vandyck et al., Novel 382 potent capsid assembly modulators regulate multiple steps of the Hepatitis B virus life-cycle, 2018.

A. D. Huber, J. J. Wolf, D. Liu, A. T. Gres, J. Tang et al., , p.385

E. M. Coonrod, Q. Yang, J. J. Kirby, K. A. Wang, Z. Sarafianos et al., The heteroaryldihydropyrimidine Bay 386 38-7690 induces hepatitis B virus core protein aggregates associated with promyelocytic leukemia nuclear 387 bodies in infected cells, vol.3, pp.131-149, 2018.

A. Corcuera, K. Stolle, S. Hillmer, S. Seitz, J. Lee et al., Novel 389 non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in 390 vitro, Antivir. Res, vol.158, pp.135-177, 2018.

V. Rat, F. Seigneuret, J. Burlaud-gaillard, R. Lemoine, C. Hourioux et al., , p.392

C. Tauber, P. Roingeard, and H. De-rocquigny, BAY 41-4109-mediated aggregation of assembled and 393 misassembled HBV capsids in cells revealed by electron microscopy, Antiv. Res, vol.169, p.104557, 2019.

M. Dusséaux, G. Masse-ranson, S. Darche, J. Ahodantin, Y. Li et al., , p.395

C. Neuveut, P. Soussan, P. Roingeard, D. Kremsdorf, D. Santo et al., Viral load affects 396 the immune response to HBV in mice with humanized immune system and liver, Gastroenterology, vol.153, pp.1647-397, 2017.

H. Strick-marchand, M. Dusséaux, S. Darche, N. D. Huntington, N. Legrand et al., , p.399

J. Ahodantin, K. Weijer, H. Spits, D. Kremsdorf, D. Santo et al., A novel mouse model for stable 400 engraftment of a human immune system and human hepatocytes, PLoS One, vol.10, p.119820, 2015.

H. Mueller, S. Wildum, S. Luangsay, J. Walther, A. Lopez et al., , p.402

J. D. Zhang, R. Schmucki, T. Racek, J. C. Hoflack, E. Kueng et al., , vol.403, p.19

G. Volz, T. Dandri, M. Yang, S. Young, J. Javanbakht et al., A novel orally available small molecule that 404 inhibits hepatitis B virus expression, J Hepatol, vol.68, pp.412-420, 2018.

A. Zlotnick, B. Venkatakrishnan, Z. Tan, E. Lewellyn, W. Turner et al., Core protein: A 406 pleiotropic keystone in the HBV lifecycle, Antiviral Res, vol.121, pp.82-93, 2015.

K. Klumpp, T. Shimada, L. Allweiss, T. Volz, M. Lütgehetmann et al.,

M. , Efficacy of NVR 3-778, Alone and in combination with pegylated Interferon, vs entecavir in 409 uPA/SCID mice with humanized livers and HBV infection, Gastroenterology, vol.154, pp.652-662, 2018.

K. Vandyck, G. Rombouts, B. Stoops, A. Tahri, A. Vos et al., , p.411

K. Vergauwen, P. Dehertogh, J. M. Berke, and P. Raboisson, Synthesis and evaluation of N-phenyl-3-412 sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV), J Med 413 Chem, vol.61, pp.6247-6260, 2018.

T. C. Tseng, C. J. Liu, T. H. Su, C. C. Wang, C. L. Chen et al., Serum hepatitis B 415 surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters, Gastroenterology, vol.416, pp.511-512, 2011.

Q. Ren, X. Liu, Z. Luo, J. Li, C. Wang et al., Discovery of hepatitis B virus 418 capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4), 2017.

, Med Chem, vol.25, pp.1042-1056

S. K. Ladner, M. J. Otto, C. S. Barker, K. Zaifert, G. H. Wang et al., Inducible 421 expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for 422 screening potential inhibitors of HBV replication, Antimicrob Agents Chemother, vol.41, pp.1715-1720, 1997.

T. Zhou, H. Guo, J. T. Guo, A. Cuconati, A. Mehta et al., Hepatitis B virus e antigen production is 424 dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA 425 surrogate in antiviral screening assays, Antiviral Res, vol.72, pp.116-124, 2006.

H. Guo, D. Jiang, T. Zhou, A. Cuconati, T. M. Block et al., Characterization of the intracellular 427 deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA 428 formation, J Virol, vol.81, pp.12472-12484, 2007.

Y. Chen, J. Sze, and M. L. He, HBV cccDNA in patients' sera as an indicator for HBV reactivation and an 430 early signal of liver damage, 36. Roingeard P, Romet-Lemonne JL, vol.10, issue.1, p.431, 2004.

D. Leturcq, A. Goudeau, and M. Essex, Hepatitis B virus core antigen (HBc Ag) accumulation in an HBV 432 nonproducer clone of HepG2-transfected cells is associated with cytopathic effect, Virology, vol.179, pp.113-120, 1990.

L. Bassit, J. Grier, M. Bennett, and R. F. Schinazi, Combinations of 2'-C-methylcytidine analogues with 434 interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system, Antivir, vol.435, 2008.

, Chem Chemother, vol.19, issue.1, pp.25-31